Acquisition: RApport Global Strategic Services
ELIQUENT Life Sciences (Eliquent), a global regulatory consulting firm in the life sciences industry, backed by GHO Capital, a specialist healthcare investor, has acquired RApport Global Strategic Services (RApport), a UK-based international regulatory consultancy supporting life science innovators gaining and maintaining authorisation for products worldwide.
The acquisition integrates RApport with Eliquent, allowing Eliquent to expand its geographic reach and portfolio of global regulatory consulting services, through blending RApport’s European expertise with Eliquent’s extensive US and Asia Pacific capabilities.
Crowe’s role and team
Crowe provided RApport vendor financial and tax due diligence. Vendor financial due diligence was led by Dan Nixon, who was supported by Jack Sargent, Charlie Breese and Jon Pena.
Vendor tax due diligence was led by Trevor Ling, who was supported by Vicki Nicoll, Glen Huxter, Raveen Somrah, Seb Harding and Louis Finn.
Client quote
“The pragmatic and collaborative Crowe team offered invaluable support throughout the diligence process and in addressing buyer queries. Their effective communication of key findings to both management and the broader advisory team fostered clarity and understanding. The work conducted by Dan and Jack on the FDD report was highly regarded; this was complemented by Trevor's invaluable assistance with tax diligence. The sale marks a significant and exciting chapter for RApport, who are thrilled to join the ELIQUENT Life Sciences family.”
Mariyam Rawat, Chief Operating Officer , RApport Global Strategic Services
